Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06493552 · ClinicalTrials.gov registry record · Phase 2
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
A Phase 2 study of Metastatic Urothelial Carcinoma and Muscle-Invasive Bladder Carcinoma, sponsored by Vasgene Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 700
- Enrollment target
- 1
- Study location
NCT06493552 is a Phase 2 study of Metastatic Urothelial Carcinoma and Muscle-Invasive Bladder Carcinoma that is actively recruiting participants, run by Vasgene Therapeutics. The registered enrollment target is 700 participants, above the 107-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (554% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06493552, a Phase 2 study of Metastatic Urothelial Carcinoma and Muscle-Invasive Bladder Carcinoma, is actively recruiting participants, sponsored by Vasgene Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Enfortumab vedotin
- DRUG SEphB4-HSA
Study Locations (1)
California
- Sarcoma Oncology Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-03-15 |
| Est. Completion | 2034-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06493552
The ClinicalTrials.gov registry entry for NCT06493552 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (554% higher). The listed sponsor is Vasgene Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06493552 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06493552 about?
NCT06493552 is a clinical study titled "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors". Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEph...
What is the current status of trial NCT06493552?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 2025-03-15. Estimated completion is 2034-08.
What conditions does trial NCT06493552 study?
This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma.
What interventions are being tested in trial NCT06493552?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Enfortumab vedotin (DRUG), SEphB4-HSA (DRUG).
Who is sponsoring clinical trial NCT06493552?
This trial is sponsored by Vasgene Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06493552 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
ARID1A and/or KDM6A Mutation and CXCL13 Expression
ACTIVE NOT RECRUITING · Phase 2
-
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Urothelial Carcinoma
All registered trials for this condition
Muscle-Invasive Bladder Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.